🇺🇸 FDA

Intelligence · Patent portfolio

Teva Pharma Patents

Full USPTO pharma patent portfolio for Teva Pharma — grant dates, expiration, and drug cross-links.

Patents
454
Expiring ≤24m
49

Quick answer

Teva Pharma has 454 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 49 expire within 24 months — use filters for patent-cliff planning.

Page 3 of 10

  1. US 9155775

    Process for manufacturing glatiramer acetate product

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9149468

    Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9139525

    N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9127057

    Anti-IL-23 heterodimer specific antibodies

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9107832

    Risperidone microparticles formed by sublimation

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9102620

    Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9090598

    Nilotinib salts and crystalline forms thereof

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9066957

    Dry powder inhaler

    Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9063153

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9018170

    Reduced volume formulation of glatiramer acetate and methods of administration

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9012641

    Crystalline forms of Prasugrel salts

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8993519

    Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor

    Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8987216

    Polysulfated glycosides and salts thereof

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8980304

    Barrel-shaped vaginal ring

    Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8975442

    Process for the preparation of and crystalline forms of optical enantiomers of modafinil

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8975279

    Amine salts of laquinimod

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8962847

    Multicomponent crystals made of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and an arylpropionic acid

    Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8946167

    Pharmaceutical compositions containing plasma protein

    Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8946300

    Use of rasagilline for the treatment of restless legs syndrome

    Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8937082

    Nilotinib salts and crystalline forms thereof

    Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8932588

    Treatment of cancer involving mutated KRAS or BRAF genes

    Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8920373

    Reduced volume formulation of glatiramer acetate and methods of administration

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8901279

    Humanized antibodies with anti-tumor activity

    Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8889213

    Processes for coating a carrier with microparticles

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8889627

    Treatment of multiple sclerosis with combination of laquinimod and fingolimod

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8889661

    Treatment of lupus nephritis using laquinimod

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8884014

    Method for purifying a fused pyrrolocarbazole derivative

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8865722

    Wet formulations of aripiprazole

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8815511

    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8809537

    N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide

    Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8809310

    Use of rasagiline for the treatment of multiple system atrophy

    Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8802854

    Crystalline forms of Prasugrel salts

    Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8759314

    Methods for treating multiple sclerosis using antisense oligonucleotides

    Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8759302

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8742129

    Crystalline forms of febuxostat

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8729305

    Process for the preparation of and crystalline forms of optical enantiomers of modafinil

    Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8722863

    Solid state forms of fidaxomycin and processes for preparation thereof

    Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8722722

    Raltegravir salts and crystalline forms thereof

    Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8709433

    Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8691872

    Dispersions of rasagiline citrate

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8680084

    Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8673322

    Crystals of laquinimod sodium, and process for the manufacture thereof

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8663681

    Oral dosage forms comprising progesterone and methods of making and using the same

    Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8663703

    Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them

    Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8653060

    Formulations of 6-mercaptopurine

    Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8653055

    Corticosteroid having low systemic absorption

    Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8648067

    Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands

    Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8647646

    Crystals of laquinimod sodium, and process for the manufacture thereof

    Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Teva Pharma have?

454 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Teva Pharma patents expire?

49 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.